Skip to main content
SpringerLink
Log in

Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly

  • Therapy in Practice
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Drug-induced parkinsonism (DIP) and tardive dyskinesia (TD) are iatrogenic consequences of antidopaminergic drugs. Both are particularly prevalent among the elderly and those with dementia. However, despite their prevalence, these disorders are often overlooked. Both entities share risk factors, physiopathological mechanisms and, to some degree, therapeutic approaches. Withdrawing the causal agent, reducing the dose or switching to a less potent antidopaminergic drug should be the first therapeutic options. Here we review both entities and emerging therapies including the recently approved drugs deutetrabenazine and valbenazine. We discuss relevant aspects for clinical practice such as new diagnostic techniques and the latest advances in the understanding of DIP and TD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Van Gerpen JA. Drug-induced Parkinsonism. Neurologist. 2002;8:363–70. https://doi.org/10.1097/01.nrl.000003012.85777.f1.

    Article  PubMed  Google Scholar 

  2. Steck H. Extrapyramidal and diencephalic syndrome in the course of largactil and serpasil treatments. Ann Med Psychol. 1954;112:737–44.

    CAS  Google Scholar 

  3. Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev. 1959;11:490–3.

    CAS  PubMed  Google Scholar 

  4. de la Fuente-Fernandez R, Schulzer M, Kuramoto L, Cragg J, Ramachandiran N, Au WL, et al. Age-specific progression of nigrostriatal dysfunction in Parkinson’s disease. Ann Neurol. 2011;69:803–10. https://doi.org/10.1002/ana.22284.

    Article  CAS  PubMed  Google Scholar 

  5. Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry. 2002;63(Suppl 4):12–9.

    CAS  PubMed  Google Scholar 

  6. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161:414–25. https://doi.org/10.1176/appi.ajp.161.3.414.

    Article  PubMed  Google Scholar 

  7. Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry. 2004;65(Suppl 9):16–20.

    CAS  PubMed  Google Scholar 

  8. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825–35. https://doi.org/10.1176/ajp.151.6.825.

    Article  CAS  PubMed  Google Scholar 

  9. de Leon J. The effect of atypical versus typical antipsychotics on tardive dyskinesia: a naturalistic study. Eur Arch Psychiatry Clin Neurosci. 2007;257:169–72. https://doi.org/10.1007/s00406-006-0705-z.

    Article  PubMed  Google Scholar 

  10. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21:151–6.

    Article  Google Scholar 

  11. Freyhan FA. Psychomotility and Parkinsonism in treatment with neuroleptic drugs. AMA Arch Neurol Psychiatry. 1957;78:465–72.

    Article  CAS  Google Scholar 

  12. Rajput AH, Rozdilsky B, Hornykiewicz O, Shannak K, Lee T, Seeman P. Reversible drug-induced Parkinsonism: clinicopathologic study of two cases. Arch Neurol. 1982;39:644–6.

    Article  CAS  Google Scholar 

  13. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of Parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology. 1999;52:1214.

    Article  CAS  Google Scholar 

  14. Llau ME, Nguyen L, Senard JM, Rascol O, Montastruc JL. Drug-induced Parkinson syndrome: 10 years of drug vigilance. Therapie. 1994;49:459–60 (in French).

    CAS  PubMed  Google Scholar 

  15. Erro R, Bhatia KP, Tinazzi M. Parkinsonism following neuroleptic exposure: a double-hit hypothesis? Mov Disord. 2015;30:780–5. https://doi.org/10.1002/mds.26209.

    Article  PubMed  Google Scholar 

  16. Stephen P, Williamson J. Drug-induced Parkinsonism in the elderly. Lancet. 1984;324:1082–3. https://doi.org/10.1016/S0140-6736(84)91516-2.

    Article  Google Scholar 

  17. López-Sendón JL, Mena MA, de Yébenes JG. Drug-induced Parkinsonism in the elderly. Drugs Aging. 2012;29:105–18.

    Article  Google Scholar 

  18. Seijo-Martinez M, Del Rio MC, Alvarez JR, Prado RS, Salgado ET, Esquete JP, et al. Prevalence of Parkinsonism and Parkinson’s disease in the Arosa Island (Spain): a community-based door-to-door survey. J Neurol Sci. 2011;304:49–54.

    Article  CAS  Google Scholar 

  19. De Lau LML, Giesbergen P, De Rijk MC, Hofman A, Koudstaal PJ, Breteler MMB. Incidence of Parkinsonism and Parkinson disease in a general population the Rotterdam Study. Neurology. 2004;63:1240–4.

    Article  Google Scholar 

  20. Benito-Leon J, Bermejo-Pareja F, Morales-Gonzalez JM, Porta-Etessam J, Trincado R, Vega S, et al. Incidence of Parkinson disease and Parkinsonism in three elderly populations of central Spain. Neurology. 2004;62:734–41.

    Article  CAS  Google Scholar 

  21. Savica R, Grossardt BR, Bower JH, Ahlskog JE, Mielke MM, Rocca WA. Incidence and time trends of drug-induced parkinsonism: a 30-year population-based study. Mov Disord. 2017;32:227–34. https://doi.org/10.1002/mds.26839.

    Article  PubMed  Google Scholar 

  22. Wenning GK, Kiechl S, Seppi K, Müller J, Högl B, Saletu M, et al. Prevalence of movement disorders in men and women aged 50–89 years (Bruneck Study cohort): a population-based study. Lancet Neurol. 2005;4:815–20. https://doi.org/10.1016/S1474-4422(05)70226-X.

    Article  PubMed  Google Scholar 

  23. Friedman JH, Trieschmann ME, Fernandez HH. Drug-induced Parkinsonism. In: Factor SA, Lang AE, Weiner WJ, editors. Drug induced movement disorders. Malden: Blackwell Publishing Inc; 2008. p. 103–39. https://doi.org/10.1002/9780470753217.ch6.

    Chapter  Google Scholar 

  24. Rajput AH, Rozdilsky B, Ang L, Rajput A. Significance of Parkinsonian manifestations in essential tremor. Can J Neurol Sci. 1993;20:114–7.

    Article  CAS  Google Scholar 

  25. Kish SJ, Shannak K, Rajput A, Deck JHN, Hornykiewicz O. Aging produces a secific pattern of striatal dopamine loss. Implication for the etiology of idiopathic Parkinson’s disease. J Neurochem. 1992;58:642–8.

    Article  CAS  Google Scholar 

  26. Sweet RA, Pollock BG, Rosen J, Mulsant BH, Altieri LP, Perel JM. Early detection of neuroleptic-induced Parkinsonism in elderly patients with dementia. J Geriatr Psychiatry Neurol. 1994;7:251–3. https://doi.org/10.1177/089198879400700411.

    Article  CAS  PubMed  Google Scholar 

  27. Rajput AH, Rajput EF. Octogenarian Parkinsonism–clinicopathological observations. Parkinsonism Relat Disord. 2017;37:50–7. https://doi.org/10.1016/j.parkreldis.2017.01.009.

    Article  PubMed  Google Scholar 

  28. Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of Parkinsonism: incidence, classification, and mortality. Ann Neurol. 1984;16:278–82. https://doi.org/10.1002/ana.410160303.

    Article  CAS  PubMed  Google Scholar 

  29. Shiroma PR, Geda YE, Mrazek DA. Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry. Pharmacogenomics. 2010;11:1305–30. https://doi.org/10.2217/pgs.10.118.

    Article  CAS  PubMed  Google Scholar 

  30. Metzer WS, Newton JEO, Steele RW, Claybrook M, Paige SR, McMillan DE, et al. HLA antigens in drug-induced Parkinsonism. Mov Disord. 1989;4:121–8. https://doi.org/10.1002/mds.870040203.

    Article  CAS  PubMed  Google Scholar 

  31. Assmann BE, Robinson RO, Surtees RAH, Bräutigam C, Heales SJR, Wevers RA, et al. Infantile Parkinsonism-dystonia and elevated dopamine metabolites in CSF. Neurology. 2004;62:1872–4.

    Article  CAS  Google Scholar 

  32. Friedman JH. Viewpoint: Challenges in our understanding of neuroleptic induced parkinsonism. Parkinsonism Relat Disord. 2014;20:1325–8. https://doi.org/10.1016/j.parkreldis.2014.09.030.

    Article  PubMed  Google Scholar 

  33. Yang S-Y, Kao Yang Y-H, Chong M-Y, Yang Y-H, Chang W-H, Lai C-S. Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. Clin Pharmacol Ther. 2007;81:586–94. https://doi.org/10.1038/sj.clpt.6100069.

    Article  CAS  PubMed  Google Scholar 

  34. Cardoso F, Camargos ST, Silva GA Jr. Etiology of parkinsonism in a Brazilian movement disorders clinic TT [Etiologia de parkinsonismo em uma clínica brasileira de distúrbios do movimento]. Arq Neuropsiquiatr. 1998;56:171–5. https://doi.org/10.1590/S0004-282X1998000200001.

    Article  CAS  PubMed  Google Scholar 

  35. Dall’Igna OP, Tort ABL, Souza DO, Lara DR. Cinnarizine has an atypical antipsychotic profile in animal models of psychosis. J Psychopharmacol. 2005;19:342–6. https://doi.org/10.1177/0269881105053284.

    Article  PubMed  Google Scholar 

  36. Brücke T, Wöber C, Podreka I, Wöber-Bingöl C, Asenbaum S, Aull S, et al. D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study. J Cereb Blood Flow Metab. 1995;15:513–8. https://doi.org/10.1038/jcbfm.1995.63.

    Article  PubMed  Google Scholar 

  37. Easterford K, Clough P, Kellett M, Fallon K, Duncan S. Reversible Parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate. Neurology. 2004;62:1435–7.

    Article  CAS  Google Scholar 

  38. Hawthorne JM, Caley CF. Extrapyramidal reactions associated with serotonergic antidepressants. Ann Pharmacother. 2015;49:1136–52. https://doi.org/10.1177/1060028015594812.

    Article  CAS  PubMed  Google Scholar 

  39. Fernandez HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinson’s disease versus dementia with Lewy bodies. J Clin Psychiatry. 2002;63:513–5.

    Article  CAS  Google Scholar 

  40. Yaw TK, Fox SH, Lang AE. Clozapine in Parkinsonian rest tremor: a review of outcomes, adverse reactions, and possible mechanisms of action. Mov Disord Clin Pract. 2016;3:116–24. https://doi.org/10.1002/mdc3.12266.

    Article  PubMed  Google Scholar 

  41. Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88:2003–10. https://doi.org/10.1212/wnl.0000000000003960.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Belleau B, Burba J, Pindell M, Reiffenstein J. Effect of deuterium substitution in sympathomimetic amines on adrenergic responses. Science. 1961;133:102–4. https://doi.org/10.1126/science.133.3446.102.

    Article  CAS  PubMed  Google Scholar 

  43. Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016;17:2461–70. https://doi.org/10.1080/14656566.2016.1258063.

    Article  CAS  PubMed  Google Scholar 

  44. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007;22:193–7.

    Article  Google Scholar 

  45. Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174:476–84. https://doi.org/10.1176/appi.ajp.2017.16091037.

    Article  PubMed  Google Scholar 

  46. Factor SA, Remington G, Comella CL, Correll CU, Burke J, Jimenez R, et al. The effects of valbenazine in participants with tardive dyskinesia: results of the 1-year KINECT 3 extension study. J Clin Psychiatry. 2017;78:1344–50. https://doi.org/10.4088/JCP.17m11777.

    Article  PubMed  Google Scholar 

  47. Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016;316:40–50. https://doi.org/10.1001/jama.2016.8655.

    Article  CAS  PubMed  Google Scholar 

  48. Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4:595–604. https://doi.org/10.1016/S2215-0366(17)30236-5.

    Article  PubMed  Google Scholar 

  49. Rodrigues FB, Duarte GS, Costa J, Ferreira JJ, Wild EJ. Tetrabenazine versus deutetrabenazine for Huntington’s disease: twins or distant cousins? Mov Disord Clin Pract. 2017;4:582–5. https://doi.org/10.1002/mdc3.12483.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Foubert-Samier A, Helmer C, Perez F, Le Goff M, Auriacombe S, Elbaz A, et al. Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort. Neurology. 2012;79:1615–21. https://doi.org/10.1212/WNL.0b013e31826e25ce.

    Article  CAS  PubMed  Google Scholar 

  51. Chung SJ, Yoo HS, Moon H, Oh JS, Kim JS, Park YH, et al. Early-onset drug-induced Parkinsonism after exposure to offenders implies nigrostriatal dopaminergic dysfunction. J Neurol Neurosurg Psychiatry. 2018;89:169–74. https://doi.org/10.1136/jnnp-2017-315873.

    Article  PubMed  Google Scholar 

  52. Shuaib UA, Rajput AH, Robinson CA, Rajput A. Neuroleptic-induced Parkinsonism: clinicopathological study. Mov Disord. 2016;31:360–5. https://doi.org/10.1002/mds.26467.

    Article  CAS  PubMed  Google Scholar 

  53. Esper CD, Factor SA. Failure of recognition of drug-induced Parkinsonism in the elderly. Mov Disord. 2008;23:401–4. https://doi.org/10.1002/mds.21854.

    Article  PubMed  Google Scholar 

  54. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30:1591–601. https://doi.org/10.1002/mds.26424.

    Article  PubMed  Google Scholar 

  55. Brigo F, Erro R, Marangi A, Bhatia K, Tinazzi M. Differentiating drug-induced Parkinsonism from Parkinson’s disease: an update on non-motor symptoms and investigations. Parkinsonism Relat Disord. 2014;20:808–14. https://doi.org/10.1016/j.parkreldis.2014.05.011.

    Article  PubMed  Google Scholar 

  56. López-Sendón Moreno JL, Alonso-Cánovas A, Buisán Catevilla J, García Barragán N, Corral Corral I, de Felipe Mimbrera A, et al. Substantia nigra echogenicity predicts response to drug withdrawal in suspected drug-induced Parkinsonism. Mov Disord Clin Pract. 2016;3:268–74. https://doi.org/10.1002/mdc3.12281.

    Article  PubMed  Google Scholar 

  57. Tinazzi M, Ottaviani S, Isaias IU, Pasquin I, Steinmayr M, Vampini C, et al. [123I]FP–CIT SPET imaging in drug-induced Parkinsonism. Mov Disord. 2008;23:1825–9. https://doi.org/10.1002/mds.22098.

    Article  PubMed  Google Scholar 

  58. Tinazzi M, Geroin C, Gandolfi M, Smania N, Tamburin S, Morgante F, et al. Pisa syndrome in Parkinson’s disease: an integrated approach from pathophysiology to management. Mov Disord. 2016;31:1785–95. https://doi.org/10.1002/mds.26829.

    Article  PubMed  Google Scholar 

  59. Cuberas-Borrós G, Lorenzo-Bosquet C, Aguadé-Bruix S, Hernández-Vara J, Pifarré-Montaner P, Miquel F, et al. Quantitative evaluation of striatal I-123-FP-CIT uptake in essential tremor and Parkinsonism. Clin Nucl Med. 2011;36:991–6. https://doi.org/10.1097/RLU.0b013e3182291a7b.

    Article  PubMed  Google Scholar 

  60. Diaz-Corrales FJ, Sanz-Viedma S, Garcia-Solis D, Escobar-Delgado T, Mir P. Clinical features and 123I-FP-CIT SPECT imaging in drug-induced Parkinsonism and Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2010;37:556–64. https://doi.org/10.1007/s00259-009-1289-4.

    Article  PubMed  Google Scholar 

  61. Rascol O, Schelosky L. 123I-metaiodobenzylguanidine scintigraphy in Parkinson’s disease and related disorders. Mov Disord. 2009;24:S732–41. https://doi.org/10.1002/mds.22499.

    Article  PubMed  Google Scholar 

  62. Lee PH, Kim JS, Shin DH, Yoon S-N, Huh K. Cardiac 123I-MIBG scintigraphy in patients with drug induced Parkinsonism. J Neurol Neurosurg Psychiatry. 2006;77:372–4.

    Article  CAS  Google Scholar 

  63. Chaudhuri KR, Healy DG, Schapira AH, National Institute for Clinical Excellence. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5:235–45. https://doi.org/10.1016/S1474-4422(06)70373-8.

    Article  PubMed  Google Scholar 

  64. Chien CP, Dimascio A, Cole JO. Antiparkinsonian agents and depot phenothiazine. Am J Psychiatry. 1974;131:86–90. https://doi.org/10.1176/ajp.131.1.86.

    Article  CAS  PubMed  Google Scholar 

  65. Keepers GA, Clappison VJ, Casey DE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry. 1983;40:1113–7.

    Article  CAS  Google Scholar 

  66. Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson’s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry. 1988;51:850–4.

    Article  CAS  Google Scholar 

  67. Gerlach J. Relationship between tardive dyskinesia, l-dopa-induced hyperkinesia and Parkinsonism. Psychopharmacology (Berl). 1977;51:259–63.

    Article  CAS  Google Scholar 

  68. Saltz BL, Woerner MG, Robinson DG, Kane JM. Side effects of antipsychotic drugs. Avoiding and minimizing their impact in elderly patients. Postgrad Med. 2000;107(169–72):175–8. https://doi.org/10.3810/pgm.2000.02.891.

    Article  Google Scholar 

  69. Ory-Magne F, Corvol J-C, Azulay J-P, Bonnet A-M, Brefel-Courbon C, Damier P, et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology. 2014;82:300–7. https://doi.org/10.1212/WNL.0000000000000050.

    Article  CAS  PubMed  Google Scholar 

  70. Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Mov Disord. 2010;25:1357–63. https://doi.org/10.1002/mds.23034.

    Article  PubMed  Google Scholar 

  71. Silver H, Geraisy N, Schwartz M. No difference in the effect of biperiden and amantadine on Parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. J Clin Psychiatry. 1995;56:167–70.

    CAS  PubMed  Google Scholar 

  72. Pahwa R, Hauser RA. ADS-5102 (Amantadine) extended release for levodopa-induced dyskinesia. JAMA Neurol. 2017;74:1507–8. https://doi.org/10.1001/jamaneurol.2017.3205.

    Article  PubMed  Google Scholar 

  73. Tinazzi M, Antonini A, Bovi T, Pasquin I, Steinmayr M, Moretto G, et al. Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced Parkinsonism. J Neurol. 2009;256:910–5. https://doi.org/10.1007/s00415-009-5039-0.

    Article  PubMed  Google Scholar 

  74. Goswami U, Dutta S, Kuruvilla K, Papp E, Perenyi A. Electroconvulsive therapy in neuroleptic-induced Parkinsonism. Biol Psychiatry. 1989;26:234–8.

    Article  CAS  Google Scholar 

  75. Berg JE. Electroconvulsive treatment of a patient with Parkinson’s disease and moderate depression. Ment Illn. 2011;3:8–10. https://doi.org/10.4081/mi.2011.e3.

    Article  Google Scholar 

  76. Moellentine C, Rummans T, Ahlskog JE, Harmsen WS, Suman VJ, O’Connor MK, et al. Effectiveness of ECT in patients with Parkinsonism. J Neuropsychiatry Clin Neurosci. 1998;10:187–93. https://doi.org/10.1176/jnp.10.2.187.

    Article  CAS  PubMed  Google Scholar 

  77. Aquino CCH, Lang AE. Tardive dyskinesia syndromes: current concepts. Parkinsonism Relat Disord. 2014;20:S113–7. https://doi.org/10.1016/s1353-8020(13)70028-2.

    Article  PubMed  Google Scholar 

  78. Fahn S, Jankovic J, Hallett M. The tardive syndromes: phenomenology, concepts on pathophysiology and treatment, and other neuroleptic-induced syndromes. Principles and practice of movement disorders. 2nd ed. Philadelphia: Elsevier; 2011. p. 415–46. https://doi.org/10.1016/b978-1-4377-2369-4.00019-6.

    Book  Google Scholar 

  79. Jeste DV, Wyatt RJ. Therapeutic strategies against tardive dyskinesia. Two decades of experience. Arch Gen Psychiatry. 1982;39:803–16.

    Article  CAS  Google Scholar 

  80. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry. 1982;39:473–81.

    Article  CAS  Google Scholar 

  81. Caligiuri MP, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly. Drugs Aging. 2000;17:363–84.

    Article  CAS  Google Scholar 

  82. Caligiuri MP, Lacro JP, Rockwell E, McAdams LA, Jeste DV. Incidence and risk factors for severe tardive dyskinesia in older patients. Br J Psychiatry. 1997;171:148–53.

    Article  CAS  Google Scholar 

  83. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord. 2006;21:589–98. https://doi.org/10.1002/mds.20823.

    Article  PubMed  Google Scholar 

  84. Carbon M, Hsieh C-H, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78:e264–78. https://doi.org/10.4088/JCP.16r10832.

    Article  PubMed  Google Scholar 

  85. Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications. J Clin Psychiatry. 2010;71:463–74. https://doi.org/10.4088/JCP.07m03890yel.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. van Os J, Fahy T, Jones P, Harvey I, Toone B, Murray R. Tardive dyskinesia: who is at risk? Acta Psychiatr Scand. 1997;96:206–16.

    Article  Google Scholar 

  87. van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal Syndromes Study III. Am J Psychiatry. 1998;155:565–7. https://doi.org/10.1176/ajp.155.4.565.

    Article  PubMed  Google Scholar 

  88. Smith JM, Baldessarini RJ. Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry. 1980;37:1368–73.

    Article  CAS  Google Scholar 

  89. Woerner MG, Alvir JM, Saltz BL, Lieberman JA, Kane JM. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry. 1998;155:1521–8. https://doi.org/10.1176/ajp.155.11.1521.

    Article  CAS  PubMed  Google Scholar 

  90. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013. https://doi.org/10.7916/D88P5Z71.

    Article  Google Scholar 

  91. Wonodi I, Adami HM, Cassady SL, Sherr JD, Avila MT, Thaker GK. Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center. J Clin Psychopharmacol. 2004;24:592–8.

    Article  Google Scholar 

  92. Tenback DE, van Harten PN, van Os J. Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis. Mov Disord. 2009;24:2309–15. https://doi.org/10.1002/mds.22707.

    Article  PubMed  Google Scholar 

  93. Ferentinos P, Dikeos D. Genetic correlates of medical comorbidity associated with schizophrenia and treatment with antipsychotics. Curr Opin Psychiatry. 2012;25:381–90. https://doi.org/10.1097/YCO.0b013e3283568537.

    Article  PubMed  Google Scholar 

  94. Ganzini L, Casey DE, Hoffman WF, McCall AL. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med. 1993;153:1469–75.

    Article  CAS  Google Scholar 

  95. Dubovsky SL, Thomas M. Tardive dyskinesia associated with fluoxetine. Psychiatr Serv. 1996;47:991–3. https://doi.org/10.1176/ps.47.9.991.

    Article  CAS  PubMed  Google Scholar 

  96. Woogen S, Graham J, Angrist B. A tardive dyskinesia-like syndrome after amitriptyline treatment. J Clin Psychopharmacol. 1981;1:34–6.

    CAS  PubMed  Google Scholar 

  97. Harrison MB, Lyons GR, Landow ER. Phenytoin and dyskinesias: a report of two cases and review of the literature. Mov Disord. 1993;8:19–27. https://doi.org/10.1002/mds.870080104.

    Article  CAS  PubMed  Google Scholar 

  98. Thach BT, Chase TN, Bosma JF. Oral facial dyskinesia accociated with prolonged use of antihistaminic decongestants. N Engl J Med. 1975;293:486–7. https://doi.org/10.1056/NEJM197509042931008.

    Article  CAS  PubMed  Google Scholar 

  99. Raja M, Azzoni A. Tardive dyskinesia after long-term veralipride treatment. J Neuropsychiatry Clin Neurosci. 2005;17:252–3. https://doi.org/10.1176/jnp.17.2.252-a.

    Article  PubMed  Google Scholar 

  100. Bordia T, McIntosh JM, Quik M. Nicotine reduces antipsychotic-induced orofacial dyskinesia in Rats. J Pharmacol Exp Ther. 2012;340:612–9. https://doi.org/10.1124/jpet.111.189100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Waddington JL. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmacology (Berl). 1990;101:431–47.

    Article  CAS  Google Scholar 

  102. Blanchet PJ, Parent M-T, Rompré PH, Lévesque D. Relevance of animal models to human tardive dyskinesia. Behav Brain Funct. 2012;8:12. https://doi.org/10.1186/1744-9081-8-12.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Loonen AJM, Ivanova SA. New insights into the mechanism of drug-induced dyskinesia. CNS Spectr. 2013;18:15–20. https://doi.org/10.1017/S1092852912000752.

    Article  PubMed  Google Scholar 

  104. Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs. 2003;17:47–62.

    Article  CAS  Google Scholar 

  105. Elkashef AM, Wyatt RJ. Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E. Schizophr Bull. 1999;25:731–40.

    Article  CAS  Google Scholar 

  106. Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain. 1998;121(Pt 1):2053–66.

    Article  Google Scholar 

  107. Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord. 2012;27:1205–15. https://doi.org/10.1002/mds.25107.

    Article  PubMed  Google Scholar 

  108. Steen VM, Løvlie R, MacEwan T, McCreadie RG. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry. 1997;2:139–45.

    Article  CAS  Google Scholar 

  109. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry. 2008;13:544–56. https://doi.org/10.1038/sj.mp.4002142.

    Article  CAS  PubMed  Google Scholar 

  110. Bordia T, Perez XA, Heiss J, Zhang D, Quik M. Optogenetic activation of striatal cholinergic interneurons regulates l-dopa-induced dyskinesias. Neurobiol Dis. 2016;91:47–58. https://doi.org/10.1016/j.nbd.2016.02.019.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Salem H, Pigott T, Zhang XY, Zeni CP, Teixeira AL. Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management. Expert Rev Neurother. 2017;17:883–94. https://doi.org/10.1080/14737175.2017.1361322.

    Article  CAS  PubMed  Google Scholar 

  112. Tarsy D. Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis. Clin Neuropharmacol. 1983;6(Suppl 1):S9–26.

    Article  Google Scholar 

  113. Tarsy D, Baldessarini RJ. Tardive dyskinesia. Annu Rev Med. 1984;35:605–23. https://doi.org/10.1146/annurev.me.35.020184.003133.

    Article  CAS  PubMed  Google Scholar 

  114. Gardos G, Casey DE, Cole JO, Perenyi A, Kocsis E, Arato M, et al. Ten-year outcome of tardive dyskinesia. Am J Psychiatry. 1994;151:836–41. https://doi.org/10.1176/ajp.151.6.836.

    Article  CAS  PubMed  Google Scholar 

  115. Labbate LA, Lande RG, Jones F, Oleshansky MA. Tardive dyskinesia in older out-patients: a follow-up study. Acta Psychiatr Scand. 1997;96:195–8. https://doi.org/10.1111/j.1600-0447.1997.tb10151.x.

    Article  CAS  PubMed  Google Scholar 

  116. Burke RE, Kang UJ, Jankovic J, Miller LG, Fahn S. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord. 1989;4:157–75. https://doi.org/10.1002/mds.870040208.

    Article  CAS  PubMed  Google Scholar 

  117. Munetz MR, Roth LH, Cornes CL. Tardive dyskinesia and informed consent: myths and realities. Bull Am Acad Psychiatry Law. 1982;10:77–88.

    CAS  PubMed  Google Scholar 

  118. Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov Disord. 1986;1:193–208. https://doi.org/10.1002/mds.870010305.

    Article  CAS  PubMed  Google Scholar 

  119. Stacy M, Jankovic J. Tardive tremor. Mov Disord. 1992;7:53–7. https://doi.org/10.1002/mds.870070110.

    Article  CAS  PubMed  Google Scholar 

  120. Fountoulakis KN, Samara M, Siapera M, Iacovides A. Tardive Tourette-like syndrome: a systematic review. Int Clin Psychopharmacol. 2011;26:237–42. https://doi.org/10.1097/YIC.0b013e32834aa924.

    Article  PubMed  Google Scholar 

  121. Tominaga H, Fukuzako H, Izumi K, Koja T, Fukuda T, Fujii H, et al. Tardive myoclonus [letter]. Lancet. 1987;1:322.

    Article  CAS  Google Scholar 

  122. Ford B, Greene P, Fahn S. Oral and genital tardive pain syndromes. Neurology. 1994;44:2115–9.

    Article  CAS  Google Scholar 

  123. Jankovic J, Casabona J. Coexistent tardive dyskinesia and parkinsonism. Clin Neuropharmacol. 1987;10:511–21.

    Article  CAS  Google Scholar 

  124. Quitkin F, Rifkin A, Gochfeld L, Klein DF. Tardive dyskinesia: are first signs reversible? Am J Psychiatry. 1977;134:84–7. https://doi.org/10.1176/ajp.134.1.84.

    Article  CAS  PubMed  Google Scholar 

  125. Gardos G, Cole JO, Tarsy D. Withdrawal syndromes associated with antipsychotic drugs. Am J Psychiatry. 1978;135:1321–4. https://doi.org/10.1176/ajp.135.11.1321.

    Article  CAS  PubMed  Google Scholar 

  126. Bergman H, Rathbone J, Agarwal V, Soares-Weiser K. Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev. 2018. https://doi.org/10.1002/14651858.CD000459.pub3.

    Article  PubMed  PubMed Central  Google Scholar 

  127. Fernandez HH, Krupp B, Friedman JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-Year follow-up. Neurology. 2001;56:805–7. https://doi.org/10.1212/WNL.56.6.805.

    Article  CAS  PubMed  Google Scholar 

  128. Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry. 2004;65:696–701.

    Article  CAS  Google Scholar 

  129. Bassitt DP, Louzã Neto MR. Clozapine efficacy in tardive dyskinesia in schizophrenic patients. Eur Arch Psychiatry Clin Neurosci. 1998;248:209–11.

    Article  CAS  Google Scholar 

  130. Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother. 2006;6:7–17. https://doi.org/10.1586/14737175.6.1.7.

    Article  CAS  PubMed  Google Scholar 

  131. Chen JJ, Ondo WG, Dashtipour K, Swope DM. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther. 2012;34:1487–504. https://doi.org/10.1016/j.clinthera.2012.06.010.

    Article  CAS  PubMed  Google Scholar 

  132. Davis MC, Miller BJ, Kalsi JK, Birkner T, Mathis MV. Efficient trial design—FDA approval of valbenazine for tardive dyskinesia. N Engl J Med. 2017;376:2503–6. https://doi.org/10.1056/NEJMp1704898.

    Article  PubMed  Google Scholar 

  133. Bergman H, Soares-Weiser K. Anticholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018. https://doi.org/10.1002/14651858.CD000204.pub2.

    Article  PubMed  PubMed Central  Google Scholar 

  134. Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81:463–9. https://doi.org/10.1212/WNL.0b013e31829d86b6.

    Article  PubMed  Google Scholar 

  135. Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson’s disease (EASE LID 3). Mov Disord. 2017;32:1701–9. https://doi.org/10.1002/mds.27131.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Ramirez-Castaneda J, Jankovic J. Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins (Basel). 2013;5:249–66. https://doi.org/10.3390/toxins5020249.

    Article  CAS  Google Scholar 

  137. Spindler MA, Galifianakis NB, Wilkinson JR, Duda JE. Globus pallidus interna deep brain stimulation for tardive dyskinesia: case report and review of the literature. Parkinsonism Relat Disord. 2013;19:141–7. https://doi.org/10.1016/j.parkreldis.2012.09.016.

    Article  PubMed  Google Scholar 

  138. Quik M, Zhang D, Perez XA, Bordia T. Role for the nicotinic cholinergic system in movement disorders; therapeutic implications. Pharmacol Ther. 2014;144:50–9. https://doi.org/10.1016/j.pharmthera.2014.05.004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018;389:67–75. https://doi.org/10.1016/j.jns.2018.02.010.

    Article  PubMed  Google Scholar 

  140. Meyer JM. Future directions in tardive dyskinesia research. J Neurol Sci. 2018;389:76–80. https://doi.org/10.1016/j.jns.2018.02.004.

    Article  PubMed  Google Scholar 

  141. Jorm AF, Jolley D. The incidence of dementia: a meta-analysis. Neurology. 1998;51:728–33.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurodegenerative Diseases, UCL Institute of Neurology, London, UK

    Carlos Estevez-Fraga & Paul Zeun

  2. Department of Neurology, Hospital Ramón y Cajal, Carretera de Colmenar Km 9.100 SN, 28034, Madrid, Spain

    Jose Luis López-Sendón Moreno

Authors
  1. Carlos Estevez-Fraga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Zeun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jose Luis López-Sendón Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jose Luis López-Sendón Moreno.

Ethics declarations

Funding

No funding was received for this study.

Conflict of interest

Jose Lopez-Sendón has received honoraria from Zambon and travel grants from Lundbeck and KRKA pharmaceuticals. He has no other conflicts of interest. Carlos Estevez-Fraga and Paul Zeun have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Estevez-Fraga, C., Zeun, P. & López-Sendón Moreno, J.L. Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly. Drugs Aging 35, 959–971 (2018). https://doi.org/10.1007/s40266-018-0590-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-018-0590-y

Search

Navigation